<SUBMISSION>
<ACCESSION-NUMBER>0001144204-03-005303
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>2
<PERIOD>20030903
<ITEMS>5
<ITEMS>7
<FILING-DATE>20030904
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>ADVANCED BIOTHERAPY INC
<CIK>0000791833
<ASSIGNED-SIC>8731
<IRS-NUMBER>510402415
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-26323
<FILM-NUMBER>03879999
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>6355 TOPANGA CANYON BLVD
<STREET2>SUITE 510
<CITY>WOODLAND HILLS
<STATE>CA
<ZIP>91367
<PHONE>8188833956
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>6355 TOPANGA CANYON BLVD
<STREET2>SUITE 510
<CITY>WOODLAND HILLS
<STATE>CA
<ZIP>91367
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>ADVANCED BIOTHERAPY CONCEPTS INC
<DATE-CHANGED>19990524
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>doc1.txt
<TEXT>
<PAGE>

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


          Date of Report (Date of earliest reported) September 3, 2003

                            Advanced Biotherapy, Inc.
             (Exact name of registrant as specified in its charter)

         Delaware                  0-26323                51-0402415
(State or other jurisdiction    (Commission         (IRS Employer
    of incorporation)            File Number)         Identification No.)

6355 Topanga Canyon Boulevard, Suite 510                            91367
Woodland Hills, California                                       (Zip Code)
(Address of principal executive offices)

Registrant's telephone number, including area code   (818) 883-6716

<PAGE>


Item 5.  OTHER EVENTS.

         The registrant published a press release on September 3, 2003 which
reported that the Board of Directors of Advanced Biotherapy, Inc. has adopted a
policy that restricts the sale of shares of the registrant's common stock by its
directors for a period of one year terminating on August 31, 2004, unless prior
to that date the registrant's common stock achieves a market price of $1.50 for
fourteen consecutive business days.

Item 7.  FINANCIAL STATEMENTS AND EXHIBITS

(c)      Exhibits.

Designation           Description of Exhibit


99.1           Press Release, dated September 3, 2003


                                   Signatures

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                 ADVANCED BIOTHERAPY, INC.
                                 (Registrant)


Date:  September 3, 2003         By:      /s/Edmond Buccellato
                                    ------------------------------------------
                                          Edmond Buccellato, President and CEO




                                INDEX TO EXHIBITS

 Exhibit              Description


 99.1           Text of Press Release, dated September 3, 2003

<PAGE>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>doc4.txt
<TEXT>
<PAGE>

                  BOARD OF DIRECTORS AGREE TO LOCK-UP AGREEMENT

"Policy restricts the sale of shares of the Company's common stock by directors"

LOS ANGELES - - (BUSINESS WIRE) - - September 3, 2003 - - Advanced Biotherapy,
Inc. (OTCBB-ADVB - News) - - a developer of new antibody therapies for treating
severe and widespread autoimmune diseases - - today announced its Board of
Directors adopted a policy that restricts the sale of shares of the Company's
common stock by directors for a period of one year terminating on August 31,
2004, unless prior to that date the Company's common stock achieves a market
price of $1.50 for fourteen consecutive trading days. Edmond F. Buccellato,
President and CEO of the Company, stated "This arrangement confirms the
directors' commitment to, and confidence in, the Company's antibody therapies,
business plan and patent portfolio. As of the date of this release, all
directors except one have entered into a written agreement with the Company
evidencing the sale restrictions. The Board continues to seek the remaining
signature from that director who is presently out of the country. The Board of
Directors also approved the policy that any director who does not enter into
their stock sale restriction agreement or comply with the sale restrictions
would be requested to resign as a director of the Company, and steps would be
taken, if necessary, to affect that result."

About Advanced Biotherapy


Advanced Biotherapy, Inc. is pioneering the development of new antibody
therapies for treating severe and widespread autoimmune diseases. Its
investigational therapies attack autoimmune diseases at their source,
neutralizing biologic imbalances that impair immune system function. Core
technology is protected under U.S. patents and patents pending for the exclusive
use of a class of antibodies to the protein known as gamma interferon and to
tumor necrosis factor-alpha for treating a range of diseases. The company is
headquartered in Woodland Hills, California. www.advancedbiotherapy.com


Statements made in this news release, other than statements of historical fact,
are forward-looking statements and are subject to a number of uncertainties that
could cause actual results to differ materially from the anticipated results or
other expectations expressed in our forward-looking statements. The risks and
uncertainties which may affect the development, operations and results of our
business include, but are not limited to the following: risks associated with
clinical trials, the uncertainties of research and product development programs,
the uncertainties of the regulatory approval process, the risks of competitive
products, the risks of our current capital resources, the uncertainties as to
the availability of future capital and our future capital requirements, and the
risks associated with the extent and breadth of the Company's patent portfolio.
Readers are cautioned not to place reliance on these forward-looking statements,
which speak only as of the date the statements were made. See the Company's
public filings with the Securities and Exchange Commission for further
information about risks and uncertainties that may affect the Company and the
results or expectations expressed in our forward-looking statements, including
the section captioned "Factors That May Affect The Company" contained in the
Company's Annual Report on Form 10-KSB/A for the fiscal year ended December 31,
2002.

----------------------------------
Contact:
     Advanced Biotherapy, Inc.
     Amy Buccellato, 818-883-6716
     www.advancedbiotherapy.com


<PAGE>

</TEXT>
</DOCUMENT>
</SUBMISSION>
